Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Centocor Inc.

(CNTO)

Discussion of competing therapies at the American College of Cardiology meeting last week underscored worries about

ReoPro

's slow market launch in high risk angioplasty.

Cowen's Stone said he was hearing consistent "yellow lights"

Read the full 375 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE